Friday, July 31, 2026

U.S. Surgeons Get Hands-On With Korea’s Game-Changing Stem Cell Therapy

Medipost's Cartistem® training program for U.S. orthopedic specialists enhances global collaboration and prepares for Phase 3 trials.

Impact of 12.5% Forced Labor Tariff on Daegu and Gyeongbuk Exports: What You Need to Know

The 12.5% forced labor tariff imposed by the U.S. has a limited impact on exports from Daegu and Gyeongbuk.

CSIS States North Korea’s Denuclearization is Not an Achievable Short-term Goal

Victor Cha argues that North Korea's denuclearization is unattainable in the short term, suggesting a cold peace strategy instead.

Tag: K-bio

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

[Interview] Excelthera Expands Portfolio With Immune Cell Culture Media, Accelerating Global Partnership Efforts

Excelthera aims to expand globally by launching new immune cell culture media and seeking global partners for collaboration.

KDDF Chief Calls for Structural Shift in Korea Biotech Beyond Technology Transfer

Dr. Park Young-min urges South Korea's biotech sector to shift from tech transfer to global collaboration for sustainable growth.

Korean MSD Partners with 13 Biotech Firms to Act as Global Collaboration Hub

Korean MSD held an Open Innovation Week to enhance collaboration with local biotech firms, aiming for technology exchanges and joint research.

Cha Biotech Announces Support of K-Bio Startups at Bio Korea 2026

Cha Biotech aims to create a global innovation ecosystem for K-Bio startups through the K-Bio CIC Open Innovation Center.

Samsung Biologics Partners with Eli Lilly: How This Open Innovation Hub Will Transform K-Bio by 2027

Samsung Biologics partners with Eli Lilly to create a biotech innovation hub in Korea, enhancing growth opportunities for local firms.

CKDB-501A vs. Botox: Can CKD BiO’s New Botulinum Toxin Compete in China’s Booming Market?

Jongkundang Bio has successfully completed Phase 3 trials in China's botulinum toxin market, signaling global expansion.

Is DD01 the Future of MASH Treatment? Insights from D&D Pharmatech’s JP Morgan Presentation

D&D Pharmatech's CEO highlights growth in K-bio at JPM Healthcare Conference, unveiling promising drug data and future plans for clinical trials.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.